Alnylam Pharmaceuticals | ALNY - 销售成本

金融业

USD

USD 5.13B

现金及等价物

USD 1.71B

USD 211.12M

USD 4.22B

USD 1.35B

USD 1.28B

USD 137.59M

USD 145.22M

2.23K

EPS每股收益

USD 1.99

股本和储备

USD 1.08B

USD 825.01M

债务利息支出

USD 69.29M

USD 26.63M

USD 2.48B

USD 37.3B

USD 205.99M

USD 898.54M

USD 137.59M

普通股股本

USD 133.44M

80.04

USD 221.65M

USD 1.17B

销售和管理费用

USD 282.51M

USD 200.15M

贸易债权人

USD 126.63M

应收帐款人

USD 883.96M

	销售成本	更改		日
Acadia Pharmaceuticals	USD 24.79M		1.43M	2026-03
Agios Pharmaceuticals	USD 1.32M		560K	2026-03
Alnylam Pharmaceuticals	USD 211.12M		56.6M	2026-03
Amgen	USD 1.6B		187M	2026-03
BioCryst Pharmaceuticals	USD 9.52M		7.34M	2025-12
BioMarin Pharmaceutical	USD 199.48M		37.93M	2026-03
Incyte	USD 104.5M		16.68M	2026-03
Ionis Pharmaceuticals	USD 3M		5M	2026-03
Moderna	USD 955M		503M	2026-03
Neurocrine Biosciences	USD 13.8M		3.8M	2026-03
Novartis	USD 3.54B		7M	2025-12
PTC Therapeutics	USD 39.61M		23.31M	2026-03
Regeneron Pharmaceuticals	USD 669.4M		84.8M	2026-03
Sangamo BioSciences	2.42M		1.11M	2024-06
Sanofi	EUR 3.76B		344M	2025-12
Sarepta Therapeutics	USD 109.46M		289.93M	2026-03
Takeda	JPY 560.54B		159.39B	2026-03
Ultragenyx Pharmaceutical	USD 30M		1000K	2026-03
Vertex Pharmaceuticals	USD 392.8M		73.2M	2026-03
Xencor	USD 61.66M		50.95M	2025-06